Search: onr:"swepub:oai:gup.ub.gu.se/65272" >
Improvement of post...
Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
-
- Fagerberg, Björn, 1943 (author)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Schuster, Herbert (author)
-
Birketvedt, Grethe Støa (author)
-
show more...
-
Tonstad, Serena (author)
-
Ohman, Karl Peter (author)
-
Gause-Nilsson, Ingrid, 1957 (author)
-
show less...
-
(creator_code:org_t)
- 2016-06-23
- 2007
- English.
-
In: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease. - : SAGE Publications. - 1479-1641. ; 4:3, s. 174-80
- Related links:
-
https://journals.sag...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- This study examined the effect of tesaglitazar (GALIDA), a dual peroxisome proliferator-activated receptor (PPAR)alpha/gamma agonist, on postprandial metabolism. This investigation was part of the Study in Insulin Resistance (SIR) (SH-SBT-0001), a randomised, double-blind, placebo-controlled study that reported improvements in fasting lipid and glucose values with tesaglitazar (0.1, 0.25, 0.5 or 1 mg once daily for 12 weeks) in hypertriglyceridaemic, abdominally obese, non-diabetic patients. A subgroup of 222 patients underwent postprandial lipid and glucose testing at baseline and treatment end. Tesaglitazar 0.25, 0.5 and 1 mg reduced postprandial area under the curve (AUC) for triglycerides by 20% (p=0.003), 30% (p<0.0001) and 41% (p<0.0001), respectively. Free fatty acid (FFA) levels were reduced by 17% with tesaglitazar 0.5 mg (p=0.002) and by 29% with tesaglitazar 1 mg (p<0.0001). Tesaglitazar significantly improved glucose tolerance and increased the proportion of patients with normal glucose tolerance as measured by the oral glucose tolerance test (OGTT). To conclude, postprandial dyslipidaemia and hyperglycaemia, indicators of increased vascular risk, were significantly improved by tesaglitazar treatment in these non-diabetic, hypertriglyceridaemic, abdominally obese subjects.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database